Back to News
Market Impact: 0.35
Arcutis Biotherapeutics, Inc. Reports Q3 2026 Net Product Revenues of $143.9 million and Raises Full-Year Guidance to $535 million–$545 million
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Arcutis Biotherapeutics reported ZORYVE net product revenues of $143.9 million for the quarter ended September 30, 2026, up 45% year over year and 11% sequentially. The article excerpt provides no earnings comparison with expectations or additional financial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
ARQT0.65
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook